Pharmaceutical Companies - ECR Pharmaceuticals Announces Re-launch of Zolpimist(R) and DexPak(R), Divestiture of Hylase(R) and Orbivan(R) Brands, and Dr. Cameron Durrant Named President and CEO
2013 MAY 18 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that its ECR Pharmaceuticals division re-launched Zolpimist® Oral Spray (zolpidem tartrate) and DexPak® Taperpaks (dexamethasone tablets) through its proprietary sales force at a series of launch meetings commencing this week.
Additionally, ECR has divested its interest in non-core products Hylase® and Orbivan®. Hylase was divested for a one-time payment in January, and Orbivan® was divested in March for $500,000 over two payments and an ongoing royalty stream ...read more
Pharmaceutical Companies - Global Medical Nutrition Market Is Expected To Grow At a Steady Pace, Clocking A CAGR Of 6.7 Percent during the Period 2012-2016
2013 MAY 18 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Research and Markets has announced the addition of the "Global Medical Nutrition Market 2012-2016" report to their offering.
The Global Medical Nutrition market includes a large number of small and large vendors. Groupe Danone S.A., Nestle Group, General Mills Inc., Abbott Laboratories, Pfizer Inc., Mead Johnson and Company, and Fresenius Kabi AG are some of the leading vendors in the market. The increasing number of mergers and acquisitions in the market is changing the market share composition frequently. In April 2012, Nestle acquired Pfizer's Infant Nutrition business for US$11.85 billion. The acquisition is expected to boost Nestle's presence in the Infant Nutrition market in China, since Pfizer had a major presence in that country ...read more
Pharmaceutical Companies - Merus Provides Enablex Operational Update
2013 MAY 11 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Merus Labs International Inc. ("Merus" or the "Company") (TSX:MSL)(NASDAQ:MSLI) is pleased to provide a corporate update regarding its flagship branded prescription medicine product Emselex®/Enablex® (darifenacin) extended release tablets.
On April 16, 2013, a wholly owned subsidiary of Merus Labs International received approval from Health Canada with regards to the marketing authorization (NOC) transfer of Emselex®/Enablex® from Novartis Pharma AG and its affiliates ("Novartis"). Merus is re-launching the product in Canada and devoting significant sales and marketing resources to these activities. ...read more
View more articles on Pharmaceutical Companies.